MBX Biosciences, Inc.
MBXFigures shown here come from public SEC filings. Dates beside each section show the available history.
How MBX Biosciences, Inc. Makes Money
No flow chart is shown because the available revenue and expense lines do not reconcile exactly. The reported financial history below remains available.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 3 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 5, 2026.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among MBX Biosciences, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2025-09-26 · Heron Patrick J: Larger than 29 of the 30 other insider purchases of Common Stock on file. SEC filing
- 2024-09-16 · Aynechi Tiba: Larger than all 30 other insider purchases of Common Stock on file. SEC filing
- 2024-09-16 · Heron Patrick J: Larger than 27 of the 30 other insider purchases of Common Stock on file. SEC filing
- 2024-09-16 · Topper James N: Larger than 27 of the 30 other insider purchases of Common Stock on file. SEC filing
Independent insiders buying near the same time
- 2025-10-17–2025-10-20: 2 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing )
- 2025-02-14–2025-02-18: 8 event(s) across 2 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing )
- 2024-09-16–2024-09-16: 17 event(s) across 15 owner(s) — A cluster counts independent reporting owners that reported purchases within a set time. Co-filers and declared affiliates count once, and duplicate reports of the same event count once. ( filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing , filing )
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-05-08 | Azoulay Salomon · Chief Medical Officer | Common Stock | S — Open market or private sale | −15,003 | 38.30 | SEC filing |
| 2026-05-08 | Azoulay Salomon · Chief Medical Officer | Common Stock | S — Open market or private sale | −55,000 | 38.38 | SEC filing |
| 2026-05-06 | Hawryluk P. Kent · President & CEO | Common Stock | S — Open market or private sale | −607 | 29.54 | SEC filing |
| 2026-05-06 | Azoulay Salomon · Chief Medical Officer | Common Stock | S — Open market or private sale | −231 | 29.54 | SEC filing |
| 2026-03-13 | Hawryluk P. Kent · President & CEO | Common Stock | P — Open market or private purchase | +18,500 | 28.41 | SEC filing |
| 2025-10-20 | Hawryluk P. Kent · President & CEO | Common Stock | P — Open market or private purchase | +20,000 | 13.64 | SEC filing |
| 2025-10-17 | Hoerter Steven L. · Director | Common Stock | P — Open market or private purchase | +20,000 | 13.25 | SEC filing |
| 2025-09-26 | Heron Patrick J · Director, 10% owner | Common Stock | P — Open market or private purchase | +666,666 | 18.00 | SEC filing |
Showing 8 of 14 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-04 | Ryder Steven · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +12,500 | SEC filing |
| 2026-06-04 | Pescovitz Ora H. · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +12,500 | SEC filing |
| 2026-06-04 | Stelzer Laurie · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +12,500 | SEC filing |
| 2026-06-04 | Mathers Edward T · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +12,500 | SEC filing |
| 2026-06-04 | Aynechi Tiba · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +12,500 | SEC filing |
| 2026-06-04 | Hoerter Steven L. · Director | Stock option (right to buy) | A — Grant, award, or other acquisition | +12,500 | SEC filing |
| 2026-06-04 | Heron Patrick J · Director, 10% owner | Stock option (right to buy) | A — Grant, award, or other acquisition | +12,500 | SEC filing |
| 2026-05-08 | Azoulay Salomon · Chief Medical Officer | Common Stock | M — Exercise or conversion of derivative security | +55,000 | SEC filing |
Showing 8 of 20 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.